Overview

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Status:
Active, not recruiting
Trial end date:
2022-01-12
Target enrollment:
Participant gender:
Summary
This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer